Recommendations

People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care.

Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.

Individualised assessment at presentation

NICE has produced a guideline on babies, children and young people's experience of healthcare.

1.1.1 Treat an acute painful sickle cell episode as an acute medical emergency. Follow locally agreed protocols for managing acute painful sickle cell episodes and/or acute medical emergencies that are consistent with this guideline.

1.1.2 Throughout an acute painful sickle cell episode, regard the patient (and/or their carer) as an expert in their condition, listen to their views and discuss with them:

  • the planned treatment regimen for the episode

  • treatment received during previous episodes

  • any concerns they may have about the current episode

  • any psychological and/or social support they may need.

1.1.3 Assess pain and use an age-appropriate pain scoring tool for all patients presenting at hospital with an acute painful sickle cell episode.

1.1.4 Offer analgesia within 30 minutes of presentation to all patients presenting at hospital with an acute painful sickle cell episode (see also the recommendations on primary analgesia).

1.1.5 Clinically assess all patients presenting at hospital with an acute painful sickle cell episode, including monitoring of:

1.1.6 Assess all patients with sickle cell disease who present with acute pain to determine whether their pain is being caused by an acute painful sickle cell episode or whether an alternative diagnosis is possible, particularly if pain is reported as atypical by the patient.

Primary analgesia

1.1.7 When offering analgesia for an acute painful sickle cell episode:

  • ask about and take into account any analgesia taken by the patient for the current episode before presentation

  • ensure that the drug, dose and administration route are suitable for the severity of the pain and the age of the patient

  • refer to the patient's individual care plan if available.

1.1.8 Offer a bolus dose of a strong opioid by a suitable administration route, in accordance with locally agreed protocols for managing acute painful sickle cell episodes, to:

  • all patients presenting with severe pain

  • all patients presenting with moderate pain who have already had some analgesia before presentation.

1.1.9 Consider a weak opioid as an alternative to a strong opioid for patients presenting with moderate pain who have not yet had any analgesia.

1.1.10 Offer all patients regular paracetamol and NSAIDs (non-steroidal anti-inflammatory drugs) by a suitable administration route, in addition to an opioid, unless contraindicated.

The use of NSAIDs should be avoided during pregnancy, unless the potential benefits outweigh the risks. NSAIDs should be avoided for treating an acute painful sickle cell episode in women in the third trimester. See the BNF for details of contraindications.

1.1.11 Do not offer pethidine for treating pain in an acute painful sickle cell episode.

Reassessment and ongoing management

1.1.12 Assess the effectiveness of pain relief:

  • every 30 minutes until satisfactory pain relief has been achieved, and at least every 4 hours thereafter

  • using an age-appropriate pain scoring tool

  • by asking questions, such as:

    • How well did that last painkiller work?

    • Do you feel that you need more pain relief?

1.1.13 If the patient has severe pain on reassessment, offer a second bolus dose of a strong opioid (or a first bolus dose if they have not yet received a strong opioid).

1.1.14 Consider patient-controlled analgesia if repeated bolus doses of a strong opioid are needed within 2 hours. Ensure that patient-controlled analgesia is used in accordance with locally agreed protocols for managing acute painful sickle cell episodes and/or acute medical emergencies.

1.1.15 Offer all patients who are taking an opioid:

  • laxatives on a regular basis

  • anti-emetics as needed

  • antipruritics as needed.

1.1.16 Monitor patients taking strong opioids for adverse events, and perform a clinical assessment (including sedation score):

  • every 1 hour for the first 6 hours

  • at least every 4 hours thereafter.

1.1.17 If the patient does not respond to standard treatment for an acute painful sickle cell episode, reassess them for the possibility of an alternative diagnosis.

1.1.18 As the acute painful sickle cell episode resolves, follow locally agreed protocols for managing acute painful sickle cell episodes to step down pharmacological treatment, in consultation with the patient.

Possible acute complications

1.1.19 Be aware of the possibility of acute chest syndrome in patients with an acute painful sickle cell episode if any of the following are present at any time from presentation to discharge:

1.1.20 Be aware of other possible complications seen with an acute painful sickle cell episode, at any time from presentation to discharge, including:

  • acute stroke

  • aplastic crisis

  • infections

  • osteomyelitis

  • splenic sequestration.

Management of underlying pathology

1.1.21 Do not use corticosteroids in the management of an uncomplicated acute painful sickle cell episode.

Non-pharmacological interventions

1.1.22 Encourage the patient to use their own coping mechanisms (for example, relaxation techniques) for dealing with acute pain.

Settings and training

1.1.23 All healthcare professionals who care for patients with an acute painful sickle cell episode should receive regular training, with topics including:

  • pain monitoring and relief

  • the ability to identify potential acute complications

  • attitudes towards and preconceptions about patients presenting with an acute painful sickle cell episode.

1.1.24 Where available, use day care settings in which staff have specialist knowledge and training for the initial assessment and treatment of patients presenting with an acute painful sickle cell episode.

1.1.25 All healthcare professionals in emergency departments who care for patients with an acute painful sickle cell episode should have access to locally agreed protocols and specialist support from designated centres.

1.1.26 Patients with an acute painful sickle cell episode should be cared for in an age-appropriate setting.

1.1.27 For pregnant women with an acute painful sickle cell episode, seek advice from the obstetrics team and refer when indicated.

Discharge information

1.1.28 Before discharge, provide the patient (and/or their carer) with information on how to continue to manage the current episode, including:

  • how to obtain specialist support

  • how to obtain additional medication

  • how to manage any potential side effects of the treatment they have received in hospital.

Terms used in this guideline

Moderate pain

Pain with a Visual Analogue Scale (VAS; or equivalent) score typically within the range of 4 to 7 (this description should not be interpreted as a strict definition and will not apply to all patients, as pain is subjective).

Patient-controlled analgesia (PCA)

A method of safely administering strong opioids which is controlled by the patient (or a nurse for nurse-controlled analgesia).

Severe pain

Pain with a VAS (or equivalent) score typically above 7 (this description should not be interpreted as a strict definition and will not apply to all patients, as pain is subjective).

  • National Institute for Health and Care Excellence (NICE)